Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer.

Abstract

Adenylate Cyclase-associated protein (CAP) is an evolutionarily conserved protein that regulates actin dynamics. Our previous study indicates that CAP1 is overexpressed in NSCLC tissues and correlated with poor clinical outcomes, but CAP1 in HeLa cells actually inhibited migration and invasion, the role of CAP was discrepancy in different cancer types. The present study aims to determine whether CAP can serve as a prognostic marker in human cancers. The CAP expression was assessed using Oncomine database to determine the gene alteration during carcinogenesis, the copy number alteration, or mutations of CAP using cBioPortal, International Cancer Genome Consortium, and Tumorscape database investigated, and the association between CAP expression and the survival of cancer patient using Kaplan-Meier plotter and PrognoScan database evaluated. Therefore, the functional correlation between CAP expression and cancer phenotypes can be established; wherein CAP might serve as a diagnostic marker or therapeutic target for certain types of cancers.

• Authors: Shuanshuan Xie, Changxing Shen, Min Tan, Ming Li, Xiaolian Song, Changhui Wang
• Journal: Oncotarget (Oncotarget) Vol. 8 Issue 16 Pg. 27216-27239 (Apr 18 2017) ISSN: 1949-2553 [Electronic] United States
• PMID: 28423713 (Publication Type: Journal Article)

Chemical References

• Adenylyl Cyclases

Topics

• Adenylyl Cyclases (genetics, metabolism)
• Cell Line, Tumor
• Computational Biology (methods)
• DNA Copy Number Variations
• Databases, Nucleic Acid
• Gene Expression Profiling
• Gene Expression Regulation, Neoplastic
• Humans
• Kaplan-Meier Estimate
• Mutation
• Neoplasms (genetics, metabolism, mortality)
• Prognosis
• Transcriptome